Efficacy Optimization for Anthracycline Regimens

About Paxman

Paxman is a global leader in the niche but impactful medical device sector of scalp cooling for chemotherapy patients. Founded in 1996, the company has established its technology as the standard of care in many regions, supported by extensive clinical evidence and inclusion in major oncology guidelines. Its commercial focus is on expanding global market access, securing reimbursement (notably with new U.S. CPT codes), and continuing research to improve efficacy, particularly for challenging chemotherapy regimens like anthracyclines. The company operates as a mission-driven, likely private entity with a deep personal connection to the patient community it serves.

Therapeutic Areas